Trials / Completed
CompletedNCT07009262
A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks
A Prospective, Non-interventional Study in Patients With Type I or II Hereditary Angioedema Using Icatibant for On-demand Treatment of Attacks
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 88 (actual)
- Sponsor
- KalVista Pharmaceuticals, Ltd. · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
Patients with HAE Type I or II who enroll in the study are asked to complete a patient diary when they experience an HAE attack. If icatibant is taken as the first treatment for the attack, the patient diary will ask questions over a 48 hour period after dosing to track the characteristics and severity of the attack along with the patient's level of anxiety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Inapplicable | Inapplicable |
Timeline
- Start date
- 2025-04-21
- Primary completion
- 2025-11-25
- Completion
- 2025-11-25
- First posted
- 2025-06-06
- Last updated
- 2026-01-13
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT07009262. Inclusion in this directory is not an endorsement.